REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christian F. Singer, Leopold Öhler, Daniel Egle, Richard Greil, Edgar Petru, Marija Balic, Maximilian Marhold, Georg Pfeiler, Christine Brunner, Werner Kwasny, Arik Armon Galid, Christoph Tinchon, Wolfgang Eisterer, Ferdinand Haslbauer, Michael Hubalek, Andreas Redl, Karin Hock, Mathias Hennebelle, Bernhard Mraz, Guenther G. Steger
Institutions: Comprehensive Cancer Center Vienna, Medical University of Vienna, St. Josef-Krankenhaus Wien, Innsbruck Medical University, Universität Innsbruck, Paracelsus Medical University, Medical University of Graz, Hanusch Hospital, LKH Hochsteiermark, Salzburger Landeskliniken, Novartis (Austria)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947544167